Disease cost of EDCs exceed £100bn a year
Published 6 Mar 2015
A series of peer-reviewed studies published today finds that human exposure to endocrine disrupting chemicals (EDCs) contribute to a number of diseases and disabilities costing Europe hundreds of billions a year.
“Estimating Burden and Disease Costs of Exposure to Endocrine Disrupting Chemicals in The European Union” is published online in the peer-reviewed Journal of Clinical Endocrinology and Metabolism.
The scientists say that the likely costs in the European Union total €157 billion (£108.5 billion) a year in health care expenses and lost earning potential.
Leading experts in this field concluded that infertility and male reproductive dysfunctions, birth defects, obesity, diabetes, cardiovascular disease, and neurobehavioral and learning disorders were among the conditions that can be partly attributed to people’s exposure to EDCs.
Two expert panels were also convened for breast cancer and female reproductive conditions; their deliberations are following an identical process and will be the basis for future reports.
Lynn Ladbrook, Chief Executive of Breast Cancer UK said; “This study brings into stark reality the potential cost to human health of daily and routine exposure to EDCs. We await the expert panel's report on breast cancer with interest, but fear that their findings are only likely to add to these already enormous costs. Action is needed now - the EU Commission must act immediately to reduce people's exposure to these harmful chemicals.”